Patent · US Active

Anti-BAFFR antibody formulations and methods of use thereof

US10899841B2 · kind B2 · utility

1Cited by

5References

10Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Marta Cosenza · Basel, CH
Christoph Heusser · Oberwil, CH
Julia Neugebauer · Munich, DE
Eveline Schaadt · Munich, DE
Stefanie Urlinger · Munich, DE
Maximilian Woisetschlaeger · Oberwil, CH

Key dates

Filing date	Mar 6, 2019
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Mar 6, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.